RS-2025-25455100

Development of a first-in-class therapeutic antibody lead targeting GTC-D1 for pulmonary fibrosis

Good T cells, Inc.

goodTcell

RESPIRATORY | **Hit**

Product Type	Antibody
Indication	Idiopathic Pulmonary Fibrosis (IPF)
Target	GTC-D1
MoA(Mechanism of Action)	The GTC-D1 neutralizing antibody can inhibit excessive macrophage activation and suppress fibroblast activation and collagen accumulation, thereby reducing fibrosis in lung tissue.
Competitiveness	Currently approved therapies for idiopathic pulmonary fibrosis (IPF), such as Pirfenidone and Nintedanib, can slow disease progression but fail to reverse or fully suppress fibrosis. Their clinical benefits are further limited by side effects, modest efficacy, and variable patient responses. Therapeutic strategies targeting the TGF-β pathway have largely failed in clinical trials due to safety concerns and the pathway's broad physiological roles. To overcome these limitations, we identified GTC-D1, which is highly upregulated in IPF patients. As a key regulator of fibrosis and immune modulation, targeting **GTC-D1** offers a promising approach to **reprogram the systemic immune network and establish an innovative treatment strategy for IPF.**
Development Stage	Hit
Route of Administration	Intranasal(i.n.) or Intravenous(i.v.)